bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer

6/19/2012 10:00:54 AM

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that its PRÉCISSM Precision Medicine biomarker profiles for non-small cell lung and colorectal cancers have been expanded. The profiles now include 13 non-small cell lung and seven colorectal cancer clinically relevant tumor biomarkers, many of which also may be used in other cancers such as melanoma.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• bioTheranostics

• Diagnostics

• Medical Dev. & Diag. - Industry